Keywords: cubist, sees, success, daptomycin, phase, ii, file
Cubist sees success with daptomycin in Phase II, to file NDA in 2001
Article | 29 September 1999
Cubist Pharmaceuticals has revealed positive interim safety data from anongoing Phase II trial of its flagship product daptomycin, a lipopetide ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
